Trial Profile
SIngle-Stage, Open-Label, Safety and Efficacy Study of Adeno-Associated Virus Encoding Human Aromatic L-Amino Acid Decarboxylase by Magnetic Resonance MR-guided Infusion Into Midbrain in Pediatric Patients With AADC Deficiency
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 26 Feb 2024
Price :
$35
*
At a glance
- Drugs Ezaladcigene resoparvovec (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms AADC
- 15 Feb 2024 Planned number of patients changed from 31 to 42.
- 24 Oct 2023 Planned End Date changed from 1 Jan 2030 to 1 Jul 2031.
- 24 Oct 2023 Planned primary completion date changed from 1 Jan 2027 to 1 Jul 2027.